nomifensine has been researched along with ANS (Autonomic Nervous System) Diseases in 1 studies
Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266)
nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brooks, DJ | 1 |
| Salmon, EP | 1 |
| Mathias, CJ | 1 |
| Quinn, N | 1 |
| Leenders, KL | 1 |
| Bannister, R | 1 |
| Marsden, CD | 1 |
| Frackowiak, RS | 1 |
1 other study available for nomifensine and ANS (Autonomic Nervous System) Diseases
| Article | Year |
|---|---|
The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.
Topics: Adult; Aged; Atrophy; Autonomic Nervous System; Autonomic Nervous System Diseases; Brain Diseases; C | 1990 |